Oncolytics Biotech Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Nachrichtenquelle: PR Newswire (engl.)
23.02.2021, 13:00  |  113   |   |   

Mayo Clinic shows pelareorep vastly improved persistence and efficacy of CAR T cell therapy leading to cures in this model

Pelareorep's synergistic effects with CAR T therapy appear to be specific and were not observed with the oncolytic virus VSV

Results demonstrate the potential of pelareorep to broaden the applicability of CAR T cells to solid tumors

SAN DIEGO, Calif. and CALGARY, AB, Feb. 23, 2021 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) announced publication of an electronic poster at the CAR-TCR Summit Europe 2021 with data from a preclinical study evaluating pelareorep and chimeric antigen receptor (CAR) T cell combination therapy in solid tumors.

Newly published results show that loading CAR T cells with pelareorep vastly improved their persistence and efficacy in a murine solid tumor model, in stark contrast to preclinical studies using intratumoral infection with the VSV oncolytic virus that weakened CAR T cells. Efficacy of pelareorep-loaded CAR T cell ("CAR/Pela") therapy was further enhanced by boosting mice 8 days later with a single intravenous dose of pelareorep ("pelareorep boost"), generating highly persistent CAR T cells, inhibition of recurrent tumor growth, and ultimately tumor cures. These synergistic immune effects were specific to pelareorep, as intravenous boosting with VSV did not augment CAR/Pela therapy or prevent the growth of recurrent tumors. Survival data from the preclinical study are shown below:

Therapy

Survival Rate at End of Study

PBS (vehicle)

0% (0/7)

CAR T

14% (1/7)

Pelareorep

0% (0/7)

Pelareorep + Pelareorep boost

0% (0/7)

CAR/Pela

57% (4/7)

CAR/Pela + pelareorep boost

100% (7/7)

Seite 1 von 4


Diesen Artikel teilen


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Oncolytics Biotech Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors Mayo Clinic shows pelareorep vastly improved persistence and efficacy of CAR T cell therapy leading to cures in this model Pelareorep's synergistic effects with CAR T therapy appear to be specific and were not observed with the oncolytic virus VSV …

Nachrichten des Autors

Titel
Titel
Titel